The complexity of this pathology and its variability among patients have long limited the development of treatments; However, in recent years, advances in the understanding of the disease and the urgency of the need for new options for innovative treatments have helped. Saphnelo® (anifrolumab), is the first biologic therapy approved in Central America and the Caribbean for the treatment of this pathology. ,
This medicine will help adult patients with moderate or severe SLE who are taking other medicines to treat the disease. The results of various clinical studies highlighted the effectiveness of the new treatment compared to other existing treatments, showing that at least 53% of patients using Safnello experienced a reduction in disease activity, improving their Quality of life improved.
“The severity of this condition can range from mild to fatal. We know that each outbreak doubles the risk of organ damage, worsening patients’ quality of life. Dr. Andres said, “Safanelo has managed to demonstrate that it can comprehensively regulate the functioning of affected organs, provide an early and sustained response and control symptoms, as well as provide patients with “May also allow more time to clear up flare-ups.” AstraZeneca director for Central America and the Caribbean.
Systemic lupus erythematosus is a complex chronic autoimmune disease that can cause long-term damage to various parts of the body, such as the joints and skin, as well as the kidneys, heart, lungs, blood vessels and brain, and even vital organs. Complications develop that lead to death. , , It is important that the patient is evaluated by an expert physician so that he or she receives appropriate care, preventive care, and education that will help improve his or her quality of life.
Its cause is unknown, because like other autoimmune diseases it can be inherited; However, some environmental triggers have been identified, such as exposure to ultraviolet rays, certain medications to treat blood pressure or infections, as well as seizures, physical exhaustion, or stress. ,
Regarding its diagnosis, the specialist may opt for a specific test, including a blood test with antinuclear antibodies (ANA), as well as blood count, urine test, kidney biopsy and other laboratory tests to rule out abnormalities in the blood test. Are included. , to assess anomalies in joints and other organs. However, it may take a long time for the patient to be correctly diagnosed.
“Early detection of this pathology is extremely relevant, as complications are minimized and appropriate treatment can be administered on a case by case basis. It can be difficult to diagnose for some patients, as the symptoms are not permanent and vary depending on the individual, sometimes even being similar to many other conditions, causing them to have a wide variety of clinical manifestations. that affect their organs,” commented Dr. Rojas.
“Unknown Enemy” campaign
With the aim of combating misinformation and lack of knowledge among the public about SLE, AstraZeneca has created a digital education and awareness platform called El Enemigo Incognito. This platform will help patients better understand the different behaviors of the pathology and understand that they are carriers of a chronic disease and that they can live with it if they treat it properly.
People will be able to access it through www.elenemigoincognito.com to get information such as risk factors, symptoms, approach recommendations, FAQs and timely diagnostic tests.
“Misinformation and variable symptoms from one patient to another make timely diagnosis difficult. It is important that people have access to quality and truthful sources of information complemented by the support of a highly trained medical team. Patients can lead normal lives if they remain under the control of their treating doctor and remain consistent with their treatment. Although lupus is considered a disabling disease, a well-cared for patient maintains quality of life and performs his or her daily activities normally,” Rojas concluded.
,
AstraZeneca
AstraZeneca is a science-based global biopharmaceutical company focused on the discovery, development and commercialization of prescription medicines to treat diseases primarily in three therapeutic areas: oncology; Cardiovascular, Renal and Metabolism and Respiratory and Immunology. Headquartered in Cambridge, United Kingdom, AstraZeneca operates in more than 100 countries and its innovative medicines are used by millions of patients around the world. Visit https://www.camcar.astrazeneca.com/es/ and follow the company on Twitter @AstraZenecaCAM.
Press Contact:
Monica Solorzano Lobo- monica.solorzano1@astrazeneca.com
Head of External Affairs and Communications, AstraZeneca